Qlt Inc (QLTI) 3.52 $QLTI
QLT synthetic retinoid comes up short in Phase 2 study
Seeking Alpha - at Seeking Alpha - Fri Dec 05, 6:50AM CST
QLTI: 3.52 (-0.02)
QLT Announces Results From Proof-of-Concept Trial With Oral Synthetic cis-Retinoid (QLT091001) in Adult Subjects With Impaired Dark Adaptation and/or Impaired Low Luminance Vision
GlobeNewswire - Fri Dec 05, 6:00AM CST
QLT Inc. (Nasdaq:QLTI) (TSX:QLT) ("QLT" or the "Company"
today announced results from its multi-center, Phase 2a clinical trial of repeated treatments of oral QLT091001 in adult subjects with early age-related macular degeneration (AMD) and impaired dark adaptation and/or impaired low luminance vision. The Company previously announced positive results from its Phase 1b clinical trials for QLT091001 in subjects with the rare inherited retinal degenerative diseases, Leber Congenital Amaurosis (LCA) and Retinitis Pigmentosa (RP).
QLTI: 3.52 (-0.02), QLT.TO: 4.10 (+0.03)
QLT Announces Departure of Chief Financial Officer
GlobeNewswire - Tue Dec 02, 6:00AM CST
QLT Inc. (Nasdaq:QLTI) (TSX:QLT) ("QLT" or the "Company" today announced that Sukhi Jagpal, Chief Financial Officer of the Company, has notified the Company that he is leaving to pursue other opportunities. Mr. Jagpal will continue in his current role through January 26, 2015. The Company will explore its options to fill the position.
QLTI: 3.52 (-0.02), QLT.TO: 4.10 (+0.03)
Seven Fat Years Of Event-Driven Investing
Chris DeMuth Jr. - at Seeking Alpha - Mon Dec 01, 6:00AM CST
OSHC: 14.37 (-0.03), QLTI: 3.52 (-0.02), VRX: 138.71 (-0.18), GCVRZ: 0.75 (unch), COWN: 4.55 (-0.03), YHOO: 50.24 (+0.30), PFN: 10.10 (-0.20), LORL: 79.60 (-0.80), ARCC: 15.13 (-0.37), DTV: 83.47 (-0.43), ABBV: 65.27 (-1.76), GPT: 6.51 (+0.06), STRZA: 28.53 (-0.14), BABA: 105.11 (+0.14)
Pharma Industry Outlook: M&A, Licensing Abound - Industry Outlook
Arpita Dutt - Zacks Investment Research - Wed Nov 19, 12:00AM CST
Pharma Industry Outlook: M&A, Licensing Abound - Industry Outlook
ACT: 259.00 (-4.00), QLTI: 3.52 (-0.02), VRX: 138.71 (-0.18), AGN: 208.47 (-2.67), SHPG: 213.70 (-0.41), AUXL: 33.11 (-0.72), ABBV: 65.27 (-1.76), SNY: 45.16 (-1.05), ABT: 43.69 (-0.77), ENDP: 68.77 (-2.45), AKRX: 41.24 (+0.38), PFE: 30.95 (-0.70), INCY: 74.65 (-1.27), SLXP: 103.36 (-2.79), MYL: 53.32 (-1.39), AMGN: 164.53 (-1.55), LLY: 69.55 (-2.06), GSK: 42.42 (-0.93), BMY: 58.75 (-0.93), ACHN: 13.28 (-0.11), MRK: 57.72 (-1.62), AZN: 71.80 (-1.80), ICPT: 137.69 (-2.48), TEVA: 55.92 (-0.92), NVS: 93.52 (-0.82)
Pharma Industry Outlook: M&A, Licensing Abound - Zacks Analyst Interviews
Arpita Dutt - Zacks Investment Research - Wed Nov 19, 12:00AM CST
Pharma Industry Outlook: M&A, Licensing Abound - Zacks Analyst Interviews
ACT: 259.00 (-4.00), QLTI: 3.52 (-0.02), VRX: 138.71 (-0.18), AGN: 208.47 (-2.67), SHPG: 213.70 (-0.41), AUXL: 33.11 (-0.72), ABBV: 65.27 (-1.76), SNY: 45.16 (-1.05), ABT: 43.69 (-0.77), ENDP: 68.77 (-2.45), AKRX: 41.24 (+0.38), PFE: 30.95 (-0.70), INCY: 74.65 (-1.27), SLXP: 103.36 (-2.79), MYL: 53.32 (-1.39), AMGN: 164.53 (-1.55), LLY: 69.55 (-2.06), GSK: 42.42 (-0.93), BMY: 58.75 (-0.93), ACHN: 13.28 (-0.11), MRK: 57.72 (-1.62), AZN: 71.80 (-1.80), ICPT: 137.69 (-2.48), TEVA: 55.92 (-0.92), NVS: 93.52 (-0.82)
QLT (QLTI) Is in Oversold Territory: What's Next? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Nov 10, 7:44AM CST
QLT (QLTI) Is in Oversold Territory: What’s Next?
QLTI: 3.52 (-0.02)
QLT Looks Undervalued With Significant Upside
Cory Renauer - at Seeking Alpha - Thu Oct 30, 11:40AM CDT
QLTI: 3.52 (-0.02)
QLT (QLTI) Reports Narrower-than-Expected Q3 Loss - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Oct 30, 8:00AM CDT
QLT Inc. (QLTI) reported a third-quarter 2014 loss of 10 cents.
QLTI: 3.52 (-0.02), VRX: 138.71 (-0.18), AUXL: 33.11 (-0.72), BMY: 58.75 (-0.93)
QLT beats by $0.02
Seeking Alpha - at Seeking Alpha - Tue Oct 28, 6:22AM CDT
QLTI: 3.52 (-0.02)
QLT Announces Third Quarter 2014 Results
GlobeNewswire - Tue Oct 28, 6:15AM CDT
QLT Inc. (Nasdaq:QLTI) (TSX:QLT) ("QLT" or the "Company" is a biotechnology company dedicated to the development and commercialization of innovative ocular products that address the unmet medical needs of patients and clinicians worldwide. The Company reported financial results today for the third quarter ended September 30, 2014. Unless otherwise specified, all amounts are reported in U.S. dollars and in accordance with U.S. GAAP.
QLTI: 3.52 (-0.02), QLT.TO: 4.10 (+0.03)
QLT Appoints Dr. Geoffrey F. Cox as Interim Chief Executive Officer
GlobeNewswire - Fri Oct 24, 6:01AM CDT
QLT Inc. (Nasdaq:QLTI) (TSX:QLT) ("QLT" or the "Company" today announced that current QLT Board member, Geoffrey F. Cox, Ph.D., has been appointed interim Chief Executive Officer, effective immediately. Dr. Cox brings more than 35 years of business and scientific leadership in the pharmaceutical and biotechnology industries to QLT, 13 years of which have been as Chairman and CEO of public companies. Dr. Cox will continue in his role as a member of the QLT Board of Directors. In conjunction with Dr. Cox's appointment, the QLT Board has disbanded its Executive Transition Committee.
QLTI: 3.52 (-0.02), QLT.TO: 4.10 (+0.03)
Global Glaucoma Treatment Market: Trends and Opportunities 2014-2019
M2 - Wed Oct 15, 6:03AM CDT
Research and Markets (http://www.researchandmarkets.com/research/h5f725/global_glaucoma) has announced the addition of the "Global Glaucoma Treatment Market: Trends and Opportunities (2014-2019)" report to their offering. This report includes detailed information on market size and share by type of drugs in glaucoma treatment sector. It also discusses key growth drivers, challenges and trends of the market. The market for glaucoma treatment has grown rapidly in the last decade, based on both increasing number of people with glaucoma and the introduction of new treatments. However, the worldwide glaucoma treatment market is expected to decline that can be attributable to price reduction of drugs due to generic availability of many brands in coming years. The glaucoma pharmaceuticals are segmented into two classes namely prostaglandins analogues (PGAs) and Non PGAs that include beta blockers, carbonic anhydrase inhibitors and alpha agonists. PGAS are the most widely prescribed drug class for glaucoma with latanoprost (brand name Xalatan) the most commonly prescribed drug. Key growth drivers of the market include rising ageing population, healthcare expenditures, medical coverage and new innovative combination drugs. The market players in medication as well as devices segments are totally different and somewhat very fragmented. Leaders in glaucoma medication space include Pfizer Inc, Alcon Inc. (Novartis), Allergan Inc and Merck and Co, Inc. Companies developing glaucoma drug-delivery devices include Ocular Therapeutix Inc, QLT Inc, pSivida Corp, Icon Bioscience Inc, Amorphex Therapeutics LLC, Euclid Systems Corp and Replenish Inc. In glaucoma laser market, top market leaders include Ellex, Lumenis, Quantel and Lightmed. Key Topics Covered: 1. Executive Summary 2. Glaucoma: A Major Cause of Vision Loss 3. Global Eye Care Market: An Analysis 4. Global Glaucoma Treatment Market: An Analysis 5. Regional Analysis: Glaucoma Treatment Market 6. Market Dynamics: Global Glaucoma Treatment Market 7. Competitive Landscape: Glaucoma Treatment Market 8. Company Profiles: Glaucoma Treatment Market For more information visit http://www.researchandmarkets.com/research/h5...l_glaucoma
AGN: 208.47 (-2.67), QLTI: 3.52 (-0.02), NVS: 93.52 (-0.82)
Acquisition, Market Activity, and Upcoming Events - Research Reports on Auxilium, Lakeland, Endo, Actavis and Celgene
PR Newswire - Tue Oct 14, 7:30AM CDT
Today, Analysts Review released its research reports regarding Auxilium Pharmaceuticals Inc. (NASDAQ: AUXL), Lakeland Industries Inc. (NASDAQ: LAKE), Endo International plc (NASDAQ: ENDP), Actavis plc (NYSE: ACT) and Celgene Corporation (NASDAQ: CELG). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/7148-100free.
ENDP: 68.77 (-2.45), ACT: 259.00 (-4.00), QLTI: 3.52 (-0.02), AUXL: 33.11 (-0.72), LAKE: 10.79 (-0.40), CELG: 114.49 (-2.25), CELGZ: 3.51 (-0.03)
Endo to Buy Auxilium for $2.6B, Diversify Portfolio - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Oct 10, 4:45PM CDT
Endo (ENDP) is set to acquire Auxilium Pharmaceuticals (AUXL) for $2.6 billion in cash as well as stock.
ENDP: 68.77 (-2.45), ACT: 259.00 (-4.00), QLTI: 3.52 (-0.02), AUXL: 33.11 (-0.72)
Market Maker Surveillance Report. FE, PBR, QLTI, CTSO, AGNC, BABA, Highest Net Buy Volume With Lowest Price Friction For Thursday, October 9th 2014
M2 - Fri Oct 10, 4:35AM CDT
BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Thursday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Thursday there were 4573 companies with "abnormal" market making, 961 companies with positive Friction Factors and 4314 companies with negative Friction Factors. Here is a list of the top companies with the highest net buy volume on Thursday and lowest price Friction (bullish). This means that there was more buying than selling in the stocks and their stock prices rose faster with less Friction. Firstenergy Corp (NYSE:FE), Petroleo Brasileiro SA Petrobras (NYSE
BR), QLT INC (NASDAQ:QLTI), CytoSorbents Corp (OTC:CTSO), American Capital Agency Corp (NASDAQ:AGNC), (NYSE:BABA). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .
PBR: 7.11 (-0.31), QLTI: 3.52 (-0.02), FE: 37.45 (-0.39), AGNC: 22.24 (-0.24), BABA: 105.11 (+0.14)
Endo Buyout Of Auxilium Joins Two Changing Firms
at Investor's Business Daily - Thu Oct 09, 6:00PM CDT
Endo International inked a deal to buy fellow specialty drugmaker Auxilium Pharmaceuticals Thursday after raising its initial bid by nearly 20% to $2.6 billion in cash and stock, or $33.25 a share. Auxilium's shares rose 9% to 32.44, while Endo's...
ENDP: 68.77 (-2.45), VRX: 138.71 (-0.18), QLTI: 3.52 (-0.02), AUXL: 33.11 (-0.72), VVUS: 3.00 (-0.01)
Nasdaq stocks posting largest volume increases
AP - Thu Oct 09, 5:02PM CDT
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
OFED: 20.00 (+0.94), QLTI: 3.52 (-0.02), QLT.TO: 4.10 (+0.03), TILE: 15.92 (+0.17), UNIS: 2.86 (-0.10), ARWR: 5.76 (-0.17), FSBW: 17.31 (+0.11), GTWN: 16.30 (-0.70), DYNT: 3.81 (unch), JAXB: 12.24 (+0.02), KFX: 6.56 (-0.09), OBCI: 3.17 (-0.14), ISSC: 2.70 (-0.12), AUXL: 33.11 (-0.72), LAKE: 10.79 (-0.40), GTIV: 19.05 (unch)
How Endo International's $2.6B Deal for Auxilium Benefits Shareholders
at The Street - Thu Oct 09, 12:53PM CDT
With this deal for Auxilium, Endo has just turned itself into a top-tier global specialty health care leader.
ENDP: 68.77 (-2.45), ABT: 43.69 (-0.77), QLTI: 3.52 (-0.02), ACT: 259.00 (-4.00), AUXL: 33.11 (-0.72)
Why Auxilium Pharmaceuticals Inc. Stock Is Soaring Today
George Budwell, The Motley Fool - Motley Fool - Thu Oct 09, 10:07AM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Auxilium Pharmaceuticals soared over 10%...
QLTI: 3.52 (-0.02), AUXL: 33.11 (-0.72)
QLT synthetic retinoid comes up short in Phase 2 study
Seeking Alpha - at Seeking Alpha - Fri Dec 05, 6:50AM CST
QLTI: 3.52 (-0.02)
QLT Announces Results From Proof-of-Concept Trial With Oral Synthetic cis-Retinoid (QLT091001) in Adult Subjects With Impaired Dark Adaptation and/or Impaired Low Luminance Vision
GlobeNewswire - Fri Dec 05, 6:00AM CST
QLT Inc. (Nasdaq:QLTI) (TSX:QLT) ("QLT" or the "Company"
today announced results from its multi-center, Phase 2a clinical trial of repeated treatments of oral QLT091001 in adult subjects with early age-related macular degeneration (AMD) and impaired dark adaptation and/or impaired low luminance vision. The Company previously announced positive results from its Phase 1b clinical trials for QLT091001 in subjects with the rare inherited retinal degenerative diseases, Leber Congenital Amaurosis (LCA) and Retinitis Pigmentosa (RP). QLTI: 3.52 (-0.02), QLT.TO: 4.10 (+0.03)
QLT Announces Departure of Chief Financial Officer
GlobeNewswire - Tue Dec 02, 6:00AM CST
QLT Inc. (Nasdaq:QLTI) (TSX:QLT) ("QLT" or the "Company"
today announced that Sukhi Jagpal, Chief Financial Officer of the Company, has notified the Company that he is leaving to pursue other opportunities. Mr. Jagpal will continue in his current role through January 26, 2015. The Company will explore its options to fill the position. QLTI: 3.52 (-0.02), QLT.TO: 4.10 (+0.03)
Seven Fat Years Of Event-Driven Investing
Chris DeMuth Jr. - at Seeking Alpha - Mon Dec 01, 6:00AM CST
OSHC: 14.37 (-0.03), QLTI: 3.52 (-0.02), VRX: 138.71 (-0.18), GCVRZ: 0.75 (unch), COWN: 4.55 (-0.03), YHOO: 50.24 (+0.30), PFN: 10.10 (-0.20), LORL: 79.60 (-0.80), ARCC: 15.13 (-0.37), DTV: 83.47 (-0.43), ABBV: 65.27 (-1.76), GPT: 6.51 (+0.06), STRZA: 28.53 (-0.14), BABA: 105.11 (+0.14)
Pharma Industry Outlook: M&A, Licensing Abound - Industry Outlook
Arpita Dutt - Zacks Investment Research - Wed Nov 19, 12:00AM CST
Pharma Industry Outlook: M&A, Licensing Abound - Industry Outlook
ACT: 259.00 (-4.00), QLTI: 3.52 (-0.02), VRX: 138.71 (-0.18), AGN: 208.47 (-2.67), SHPG: 213.70 (-0.41), AUXL: 33.11 (-0.72), ABBV: 65.27 (-1.76), SNY: 45.16 (-1.05), ABT: 43.69 (-0.77), ENDP: 68.77 (-2.45), AKRX: 41.24 (+0.38), PFE: 30.95 (-0.70), INCY: 74.65 (-1.27), SLXP: 103.36 (-2.79), MYL: 53.32 (-1.39), AMGN: 164.53 (-1.55), LLY: 69.55 (-2.06), GSK: 42.42 (-0.93), BMY: 58.75 (-0.93), ACHN: 13.28 (-0.11), MRK: 57.72 (-1.62), AZN: 71.80 (-1.80), ICPT: 137.69 (-2.48), TEVA: 55.92 (-0.92), NVS: 93.52 (-0.82)
Pharma Industry Outlook: M&A, Licensing Abound - Zacks Analyst Interviews
Arpita Dutt - Zacks Investment Research - Wed Nov 19, 12:00AM CST
Pharma Industry Outlook: M&A, Licensing Abound - Zacks Analyst Interviews
ACT: 259.00 (-4.00), QLTI: 3.52 (-0.02), VRX: 138.71 (-0.18), AGN: 208.47 (-2.67), SHPG: 213.70 (-0.41), AUXL: 33.11 (-0.72), ABBV: 65.27 (-1.76), SNY: 45.16 (-1.05), ABT: 43.69 (-0.77), ENDP: 68.77 (-2.45), AKRX: 41.24 (+0.38), PFE: 30.95 (-0.70), INCY: 74.65 (-1.27), SLXP: 103.36 (-2.79), MYL: 53.32 (-1.39), AMGN: 164.53 (-1.55), LLY: 69.55 (-2.06), GSK: 42.42 (-0.93), BMY: 58.75 (-0.93), ACHN: 13.28 (-0.11), MRK: 57.72 (-1.62), AZN: 71.80 (-1.80), ICPT: 137.69 (-2.48), TEVA: 55.92 (-0.92), NVS: 93.52 (-0.82)
QLT (QLTI) Is in Oversold Territory: What's Next? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Nov 10, 7:44AM CST
QLT (QLTI) Is in Oversold Territory: What’s Next?
QLTI: 3.52 (-0.02)
QLT Looks Undervalued With Significant Upside
Cory Renauer - at Seeking Alpha - Thu Oct 30, 11:40AM CDT
QLTI: 3.52 (-0.02)
QLT (QLTI) Reports Narrower-than-Expected Q3 Loss - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Oct 30, 8:00AM CDT
QLT Inc. (QLTI) reported a third-quarter 2014 loss of 10 cents.
QLTI: 3.52 (-0.02), VRX: 138.71 (-0.18), AUXL: 33.11 (-0.72), BMY: 58.75 (-0.93)
QLT beats by $0.02
Seeking Alpha - at Seeking Alpha - Tue Oct 28, 6:22AM CDT
QLTI: 3.52 (-0.02)
QLT Announces Third Quarter 2014 Results
GlobeNewswire - Tue Oct 28, 6:15AM CDT
QLT Inc. (Nasdaq:QLTI) (TSX:QLT) ("QLT" or the "Company"
is a biotechnology company dedicated to the development and commercialization of innovative ocular products that address the unmet medical needs of patients and clinicians worldwide. The Company reported financial results today for the third quarter ended September 30, 2014. Unless otherwise specified, all amounts are reported in U.S. dollars and in accordance with U.S. GAAP. QLTI: 3.52 (-0.02), QLT.TO: 4.10 (+0.03)
QLT Appoints Dr. Geoffrey F. Cox as Interim Chief Executive Officer
GlobeNewswire - Fri Oct 24, 6:01AM CDT
QLT Inc. (Nasdaq:QLTI) (TSX:QLT) ("QLT" or the "Company"
today announced that current QLT Board member, Geoffrey F. Cox, Ph.D., has been appointed interim Chief Executive Officer, effective immediately. Dr. Cox brings more than 35 years of business and scientific leadership in the pharmaceutical and biotechnology industries to QLT, 13 years of which have been as Chairman and CEO of public companies. Dr. Cox will continue in his role as a member of the QLT Board of Directors. In conjunction with Dr. Cox's appointment, the QLT Board has disbanded its Executive Transition Committee. QLTI: 3.52 (-0.02), QLT.TO: 4.10 (+0.03)
Global Glaucoma Treatment Market: Trends and Opportunities 2014-2019
M2 - Wed Oct 15, 6:03AM CDT
Research and Markets (http://www.researchandmarkets.com/research/h5f725/global_glaucoma) has announced the addition of the "Global Glaucoma Treatment Market: Trends and Opportunities (2014-2019)" report to their offering. This report includes detailed information on market size and share by type of drugs in glaucoma treatment sector. It also discusses key growth drivers, challenges and trends of the market. The market for glaucoma treatment has grown rapidly in the last decade, based on both increasing number of people with glaucoma and the introduction of new treatments. However, the worldwide glaucoma treatment market is expected to decline that can be attributable to price reduction of drugs due to generic availability of many brands in coming years. The glaucoma pharmaceuticals are segmented into two classes namely prostaglandins analogues (PGAs) and Non PGAs that include beta blockers, carbonic anhydrase inhibitors and alpha agonists. PGAS are the most widely prescribed drug class for glaucoma with latanoprost (brand name Xalatan) the most commonly prescribed drug. Key growth drivers of the market include rising ageing population, healthcare expenditures, medical coverage and new innovative combination drugs. The market players in medication as well as devices segments are totally different and somewhat very fragmented. Leaders in glaucoma medication space include Pfizer Inc, Alcon Inc. (Novartis), Allergan Inc and Merck and Co, Inc. Companies developing glaucoma drug-delivery devices include Ocular Therapeutix Inc, QLT Inc, pSivida Corp, Icon Bioscience Inc, Amorphex Therapeutics LLC, Euclid Systems Corp and Replenish Inc. In glaucoma laser market, top market leaders include Ellex, Lumenis, Quantel and Lightmed. Key Topics Covered: 1. Executive Summary 2. Glaucoma: A Major Cause of Vision Loss 3. Global Eye Care Market: An Analysis 4. Global Glaucoma Treatment Market: An Analysis 5. Regional Analysis: Glaucoma Treatment Market 6. Market Dynamics: Global Glaucoma Treatment Market 7. Competitive Landscape: Glaucoma Treatment Market 8. Company Profiles: Glaucoma Treatment Market For more information visit http://www.researchandmarkets.com/research/h5...l_glaucoma
AGN: 208.47 (-2.67), QLTI: 3.52 (-0.02), NVS: 93.52 (-0.82)
Acquisition, Market Activity, and Upcoming Events - Research Reports on Auxilium, Lakeland, Endo, Actavis and Celgene
PR Newswire - Tue Oct 14, 7:30AM CDT
Today, Analysts Review released its research reports regarding Auxilium Pharmaceuticals Inc. (NASDAQ: AUXL), Lakeland Industries Inc. (NASDAQ: LAKE), Endo International plc (NASDAQ: ENDP), Actavis plc (NYSE: ACT) and Celgene Corporation (NASDAQ: CELG). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/7148-100free.
ENDP: 68.77 (-2.45), ACT: 259.00 (-4.00), QLTI: 3.52 (-0.02), AUXL: 33.11 (-0.72), LAKE: 10.79 (-0.40), CELG: 114.49 (-2.25), CELGZ: 3.51 (-0.03)
Endo to Buy Auxilium for $2.6B, Diversify Portfolio - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Oct 10, 4:45PM CDT
Endo (ENDP) is set to acquire Auxilium Pharmaceuticals (AUXL) for $2.6 billion in cash as well as stock.
ENDP: 68.77 (-2.45), ACT: 259.00 (-4.00), QLTI: 3.52 (-0.02), AUXL: 33.11 (-0.72)
Market Maker Surveillance Report. FE, PBR, QLTI, CTSO, AGNC, BABA, Highest Net Buy Volume With Lowest Price Friction For Thursday, October 9th 2014
M2 - Fri Oct 10, 4:35AM CDT
BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Thursday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Thursday there were 4573 companies with "abnormal" market making, 961 companies with positive Friction Factors and 4314 companies with negative Friction Factors. Here is a list of the top companies with the highest net buy volume on Thursday and lowest price Friction (bullish). This means that there was more buying than selling in the stocks and their stock prices rose faster with less Friction. Firstenergy Corp (NYSE:FE), Petroleo Brasileiro SA Petrobras (NYSE
BR), QLT INC (NASDAQ:QLTI), CytoSorbents Corp (OTC:CTSO), American Capital Agency Corp (NASDAQ:AGNC), (NYSE:BABA). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net . PBR: 7.11 (-0.31), QLTI: 3.52 (-0.02), FE: 37.45 (-0.39), AGNC: 22.24 (-0.24), BABA: 105.11 (+0.14)
Endo Buyout Of Auxilium Joins Two Changing Firms
at Investor's Business Daily - Thu Oct 09, 6:00PM CDT
Endo International inked a deal to buy fellow specialty drugmaker Auxilium Pharmaceuticals Thursday after raising its initial bid by nearly 20% to $2.6 billion in cash and stock, or $33.25 a share. Auxilium's shares rose 9% to 32.44, while Endo's...
ENDP: 68.77 (-2.45), VRX: 138.71 (-0.18), QLTI: 3.52 (-0.02), AUXL: 33.11 (-0.72), VVUS: 3.00 (-0.01)
Nasdaq stocks posting largest volume increases
AP - Thu Oct 09, 5:02PM CDT
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
OFED: 20.00 (+0.94), QLTI: 3.52 (-0.02), QLT.TO: 4.10 (+0.03), TILE: 15.92 (+0.17), UNIS: 2.86 (-0.10), ARWR: 5.76 (-0.17), FSBW: 17.31 (+0.11), GTWN: 16.30 (-0.70), DYNT: 3.81 (unch), JAXB: 12.24 (+0.02), KFX: 6.56 (-0.09), OBCI: 3.17 (-0.14), ISSC: 2.70 (-0.12), AUXL: 33.11 (-0.72), LAKE: 10.79 (-0.40), GTIV: 19.05 (unch)
How Endo International's $2.6B Deal for Auxilium Benefits Shareholders
at The Street - Thu Oct 09, 12:53PM CDT
With this deal for Auxilium, Endo has just turned itself into a top-tier global specialty health care leader.
ENDP: 68.77 (-2.45), ABT: 43.69 (-0.77), QLTI: 3.52 (-0.02), ACT: 259.00 (-4.00), AUXL: 33.11 (-0.72)
Why Auxilium Pharmaceuticals Inc. Stock Is Soaring Today
George Budwell, The Motley Fool - Motley Fool - Thu Oct 09, 10:07AM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Auxilium Pharmaceuticals soared over 10%...
QLTI: 3.52 (-0.02), AUXL: 33.11 (-0.72)
